Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.

This article has no abstract
Epistemonikos ID: 2cff5f647a8edb9f63d471c6ddfb67bc94e87cfa
First added on: Jul 16, 2020